MedPage Today on MSN
Medicare Decision on GLP-1s Soon; Inhaled Insulin Under Review for Kids; 'Manopause'
Rapid-acting inhaled insulin (Afrezza) is under FDA review for children ages 4 to 17 with diabetes, said maker MannKind. If ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback